SCHEMBL8541271

SCHEMBL8541271

C=Cc1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@@H]3CCC4=CC5(CC[C@@H]4[C@H]32)SCCS5)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 9/20 0.39
▸ AR P10275 9/20 0.38
▸ NR3C1 P04150 8/20 0.38
▸ CYP3A4 P08684 1/20 0.36
▸ STS P08842 1/20 0.34
▸ ESR1 P03372 2/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ CHRM2 P08172 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ PDK1 Q15118 1/20 0.30
▸ PDK2 Q15119 1/20 0.30
▸ PDK3 Q15120 1/20 0.30
▸ PDK4 Q16654 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8540866 0.82 CYP19A1 (0.35) PGRARCYP3A4STSESR1
SCHEMBL8541045 0.81 PGR (0.59) PGRARNR3C1CYP3A4ESR1
SCHEMBL22861553 0.73 NR3C1 (0.71) PGRARNR3C1CYP3A4
SCHEMBL21143400 0.72 NR3C1 (0.72) PGRARNR3C1CYP3A4
SCHEMBL21143415 0.72 ESR1 (0.37) PGRARNR3C1CYP3A4STS
SCHEMBL20048226 0.72 ESR1 (0.37) PGRARNR3C1CYP3A4STS
SCHEMBL20048225 0.72 ESR1 (0.37) PGRARNR3C1CYP3A4STS
SCHEMBL21470229 0.71 NR3C1 (0.73) PGRARNR3C1CYP3A4
SCHEMBL9019868 0.71 PDK1 (0.36) PGRARNR3C1CYP3A4STS
SCHEMBL9019805 0.71 PGR (0.35) PGRARNR3C1CYP3A4STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000051623-A2 INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION (US) 2000-09-08 — — WO disclosed
EP-0404283-B1 11-Beta-aryl-4-estrene, method for its production and its use as a medicine SCHERING AG (DE) 1996-05-08 — — EP disclosed
EP-0404283-A2 11-Beta-aryl-4-estrene, method for its production and its use as a medicine SCHERING AKTIENGESELLSCHAFT (DE) 1990-12-27 — — EP disclosed
Send feedback